Presenting author
Avia Merenlender Wagner
3 presentations
PS01-1228. Exposure–response relationship of once-monthly subcutaneous olanzapine (TV-44749) for clinical and functional outcomes in schizophrenia
PS02-2246. Exposure–response efficacy and safety analysis of subcutaneous LAI olanzapine (TV-44749): clinical application for dosing and switching strategies
PS02-2247. Joint population pharmacokinetic model of olanzapine following oral, intramuscular, and subcutaneous administration to support TV-44749 dose recommendations and switching strategies